Back to top
more

Athersys, Inc. (ATHX)

(Delayed Data from NSDQ)

$1.55 USD

1.55
403,009

+0.04 (2.65%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.55 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal

by Zacks Equity Research

While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line data shows evidence of therapeutic impact.

Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA

by Zacks Equity Research

The FDA accepts and grants priority review to Regeneron (REGN) and Sanofi's sBLA for Dupixent to treat eosinophilic esophagitis in patients aged 12 years and older. A decision is due on Aug 3, 2022.

Vertex's (VRTX) Pain Candidate Meets Goal in Two Studies

by Zacks Equity Research

Vertex's (VRTX) two phase II proof-of-concept studies evaluating VX-548 for acute pain following abdominoplasty surgery or bunionectomy surgery meets the primary endpoint.

Blueprint Medicines (BPMC) Gets EU Nod for Ayvakyt in SM

by Zacks Equity Research

The European Commission approves Blueprint Medicines' (BPMC) Ayvakyt for treating adult patients with advanced systemic mastocytosis.

Rezolute (RZLT) Posts Positive Data From Congenital HI Study

by Zacks Equity Research

Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperinsulinism.

Epizyme (EPZM) Down More Than 50% in Past 3 Months: Here's Why

by Zacks Equity Research

Epizyme's (EPZM) lead drug, Tazverik, is approved to treat follicular lymphoma and epithelioid sarcoma in the United States. Stiff competition in the target remains an overhang.

AnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet Goal

by Zacks Equity Research

AnaptysBio's (ANAB) phase II study evaluating imsidolimab for treating moderate-to-severe acne, fails to show improvement over placebo in top-line primary or secondary endpoints. Shares down.

Acadia (ACAD) Stock Up on FDA's Action Date for Nuplazid sNDA

by Zacks Equity Research

Acadia (ACAD) gets an action date of Aug 4, 2022, from the FDA for its resubmitted sNDA for pimavanserin to treat hallucinations and delusions associated with Alzheimer's disease psychosis.

Horizon's (HZNP) sBLA for Krystexxa Gets FDA Priority Review

by Zacks Equity Research

The FDA grants priority review to Horizon's (HZNP) sBLA for Krystexxa plus methotrexate to treat people living with uncontrolled gout. A decision is due on Jul 7, 2022.

Is Athersys, Inc. (ATHX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Athersys, Inc. (ATHX) and Gamida Cell (GMDA) have performed compared to their sector so far this year.

Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Amneal Pharmaceuticals (AMRX) and Athersys, Inc. (ATHX) have performed compared to their sector so far this year.

Implied Volatility Surging for Athersys (ATHX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.

Athersys, Inc. (ATHX) Upgraded to Buy: Here's Why

by Zacks Equity Research

Athersys, Inc. (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Why Investors Should Hold on to Universal Health (UHS) Stock

by Zacks Equity Research

Universal Health (UHS) can bank on balance sheet strength for future acquisitions to grow its business inorganically.

Is the Options Market Predicting a Spike in Athersys (ATHX) Stock?

by Zacks Equity Research

Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Athersys (ATHX) Stock?

by Zacks Equity Research

Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.

Do Options Traders Know Something About Athersys (ATHX) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.

Athersys, Inc. (ATHX) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Athersys, Inc. (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Athersys (ATHX) Surges: Stock Moves 8.8% Higher

by Zacks Equity Research

Athersys (ATHX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Do Options Traders Know Something About Athersys (ATHX) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.

Athersys Gets FDA's RMAT Designation for Cell Therapy in ARDS

by Zacks Equity Research

The FDA bestows a Regenerative Medicine Advanced Therapy status on Athersys' (ATHX) MultiStem cell therapy candidate for treating acute respiratory distress syndrome.

    New Strong Sell Stocks for August 25th

    by Zacks Equity Research

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

    Sweta Jaiswal, FRM headshot

    Biotech ETFs Gaining on Progress in Coronavirus Treatment

    by Sweta Jaiswal, FRM

    The race to introduce vaccine and treatment for coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.

    Pluristem Up on Cell Therapy Treatment of Coronavirus Patient

    by Zacks Equity Research

    Pluristem (PSTI) gains on the treatment of first patient suffering from COVID-19 complications with its cell therapy.

    Ekta Bagri headshot

    Will Stem Cell Therapies Aid in Fight Against Coronavirus?

    by Ekta Bagri

    With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.